See more : NIO Inc. (NIO) Income Statement Analysis – Financial Results
Complete financial analysis of NervGen Pharma Corp. (NGENF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NervGen Pharma Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hexaom S.A. (ALHEX.PA) Income Statement Analysis – Financial Results
- Viking Energy Group, Inc. (VKIN) Income Statement Analysis – Financial Results
- MicroStrategy Incorporated (0A7O.L) Income Statement Analysis – Financial Results
- Henderson High Income Trust plc (HHI.L) Income Statement Analysis – Financial Results
- SOLBAR NINGBO PROTEIN TECH CO L (603231.SS) Income Statement Analysis – Financial Results
NervGen Pharma Corp. (NGENF)
About NervGen Pharma Corp.
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 145.00K | 115.11K | 42.63K | 39.65K | 38.22K | 19.76K | 0.00 |
| Gross Profit | -145.00K | -115.11K | -42.63K | -39.65K | -38.22K | -19.76K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 8.05M | 16.61M | 6.87M | 6.16M | 6.45M | 780.40K | 0.00 |
| General & Administrative | 9.73M | 6.34M | 5.94M | 5.03M | 3.38M | 578.08K | 11.81K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.73M | 6.34M | 5.94M | 5.03M | 3.38M | 578.08K | 11.81K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.78M | 23.03M | 12.81M | 11.20M | 9.86M | 1.36M | 11.81K |
| Cost & Expenses | 17.78M | 23.03M | 12.81M | 11.20M | 9.86M | 1.36M | 11.81K |
| Interest Income | 550.07K | 201.40K | 29.42K | 18.85K | 98.83K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 514.60K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 55.04K | 115.11K | 42.63K | 39.65K | 38.22K | 19.76K | 12.89K |
| EBITDA | -17.72M | -22.71M | -12.77M | -11.16M | -9.83M | -1.34M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -17.78M | -22.82M | -12.87M | -11.19M | -9.86M | -1.36M | -11.81K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.61M | 2.30M | 84.65K | 9.74K | 98.83K | 0.00 | 1.07K |
| Income Before Tax | -22.38M | -20.72M | -12.73M | -11.19M | -9.77M | -1.36M | -11.81K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 514.60K | -84.65K | -9.74K | -133.64K | -141.38K | -12.89K |
| Net Income | -22.38M | -20.72M | -12.73M | -11.19M | -9.77M | -1.36M | -11.81K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.38 | -0.39 | -0.32 | -0.35 | -0.38 | -0.05 | 0.00 |
| EPS Diluted | -0.38 | -0.39 | -0.32 | -0.35 | -0.38 | -0.05 | 0.00 |
| Weighted Avg Shares Out | 59.29M | 52.65M | 39.29M | 32.11M | 25.90M | 27.20M | 27.20M |
| Weighted Avg Shares Out (Dil) | 59.29M | 52.65M | 39.29M | 32.11M | 25.90M | 27.20M | 27.20M |
NervGen Pharma Reports Q2 2023 Financial Results and Operational Updates
Landmark Phase 1a/2b clinical trial of NVG-291 proceeds with recruitment of individuals with spinal cord injury; results expected in mid-2024 Seasoned life sciences executive, Mike Kelly, appointed President & CEO Awarded grant of up to US$3.18 million from Wings for...
NervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approval
Recruitment of individuals with spinal cord injury (SCI) initiated at Shirley Ryan AbilityLab in Chicago Chronic SCI cohort results expected in mid-2024 and subacute SCI cohort results in late 2024/early 2025 Vancouver, British Columbia--(Newsfile Corp. - August 8, 2023) -...
NervGen Pharma to Present at Upcoming Investor Conferences
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that...
Trading Ideas On The Upcoming CTAD 2022 Conference
The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.
NervGen: Modulating Immune Cells For Spinal Cord Injury, Multiple Sclerosis And Parkinson's
NervGen is a Canadian early-stage biotech company with unprecedented preclinical work in spinal cord injury and multiple sclerosis. The company is finalizing a Phase 1 clinical trial for its ‘pipeline in a product' NVG-291 to assess safety, tolerability and metabolism.
NervGen Pharma to Present at 2022 Virtual Growth Conference Presented by Maxim Group
Engages Apaton Finance to Provide Investor Relations Services in EuropeVancouver, British Columbia--(Newsfile Corp. - March 23, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for...
NervGen Presents Interim Phase 1 Clinical Trial Data for NVG-291 at the American Neurological Association 14th Annual Meeting
NVG-291 Demonstrated to be Well Tolerated Along with a Favorable Pharmacokinetic ProfileVancouver, British Columbia--(Newsfile Corp. - October 18, 2021) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative...
U.S. Senate Defense Bill Includes NervGen Supported Language on Promise of Brain Plasticity Therapeutics for Traumatic Brain Injury
Cincinnati, Ohio--(Newsfile Corp. - October 4, 2021) - NervGen Pharma Corp., through its subsidiary, NervGen US Inc., (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, applauds...
NervGen Pharma Partners with Imeka to Use Novel Neuroimaging Technology in Clinical Trials
Vancouver, British Columbia--(Newsfile Corp. - September 27, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage today announced a...
Encode Ideas, L.P. Announces the Initiation of Research Coverage on NervGen Pharma Corp.
Dover, Delaware--(Newsfile Corp. - September 13, 2021) - Encode Ideas, L.P. Initiates Research on NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF). The full research publication can be found on our website at www.encodelp.com, or by clicking here.Encode Ideas, L.P., a...
Source: https://incomestatements.info
Category: Stock Reports